Neurogene Inc.
NGNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3 | $3 | $3 | $42 |
| Gross Profit | -$2 | -$3 | -$3 | -$42 |
| % Margin | -251% | – | – | – |
| R&D Expenses | $61 | $44 | $48 | $42 |
| G&A Expenses | $23 | $11 | $9 | $8 |
| SG&A Expenses | $23 | $11 | $9 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$3 | -$3 | -$42 |
| Operating Expenses | $80 | $52 | $53 | $8 |
| Operating Income | -$83 | -$56 | -$57 | -$51 |
| % Margin | -8,930.3% | – | – | – |
| Other Income/Exp. Net | $7 | $19 | $1 | $0 |
| Pre-Tax Income | -$75 | -$36 | -$55 | -$51 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$75 | -$36 | -$55 | -$51 |
| % Margin | -8,123.7% | – | – | – |
| EPS | -4.28 | -2.83 | -4.3 | -0.92 |
| % Growth | -51.2% | 34.2% | -367.4% | – |
| EPS Diluted | -4.28 | -2.83 | -4.3 | -0.92 |
| Weighted Avg Shares Out | 18 | 13 | 13 | 55 |
| Weighted Avg Shares Out Dil | 18 | 13 | 13 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $3 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $3 | $1 |
| EBITDA | -$72 | -$52 | -$52 | -$50 |
| % Margin | -7,771.4% | – | – | – |